Compound Profile
Zolpidem
Compound profile with evidence, safety, and practical fit.
Review needed — Review medications, pregnancy status, chronic conditions, and clinician guidance before use. Details
At a glance
From this profile's structured data- Evidence
- Grade C
- Profile context
- GABA-A receptor positive modulation, central nervous system sedation
Controlled medication safety warning
U.S. Schedule IV controlled substance. This research-only reference has not completed profile-level contraindication, interaction, or dosing review, so blank safety fields must not be interpreted as evidence of safety.
- Use only in lawful prescribing and dispensing contexts under qualified clinical supervision.
- Do not use this page to start, stop, change, share, source, or dose a controlled medication.
- Consult the current product-specific prescribing information for boxed warnings, contraindications, interactions, and monitoring requirements.
Quick stats
- Evidence level
- Limited evidence
- Typical onset
- Varies by prep
- Safety rating
- Review needed: Safety review pending
- Best for
- GABA A Receptor Positive Modulation, Central Nervous System Sedation
Botanical Context
Source botanicals and comparison guides related to Zolpidem.
Safety
Safety & Cautions
Review medications, pregnancy status, chronic conditions, and clinician guidance before use.
High caution
Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.
- Interaction-AwareMedication or interaction context is explicitly noted.
- Stimulant-Like ProfileStimulant-like or activating caution language is present.
Evidence Summary
Profile-wide ·C LimitedEvidence lens
Read as directional context, not settled clinical proof.
Human clinical evidence: Present in source signals
Mechanistic / preclinical: Mechanism mapped
Research maturity: Emerging research — main contexts: GABA A Receptor Positive Modulation · Central Nervous System Sedation
Safety boundary: Safety note available — Review medications, pregnancy status, chronic conditions, and clinician guidance before use.
Confidence estimate based on the design quality and consistency of published clinical trials.
Zolpidem has a limited evidence rating.
Grade C: Limited Evidence
Evaluation of methodological rigor, population reach, and evidence alignment.
- Design Match
- Meta analysis
- Risk of Bias
- Low
- Consistency
- Not assessed
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
- Strong
- Multiple RCTs, consistent direction, adequate effect size
- Moderate
- Some RCTs or consistent observational data in humans
- Preliminary / Mixed
- Animal or in-vitro only, or conflicting human data
- Traditional / Theoretical
- Traditional use only; no controlled human trials
Clinical Study Summaries (3)2 human evidence sources · 0 human trials · Participant totals not consistently reported · Consistency not yet classifiable
Filter by study class
Showing 3 of 3 studies.
What the evidence actually shows
This table contains 3 structured sources, including 2 human evidence sources; 0 are human trials.
| Study | Design | N | Dose | Duration | Population | Outcome | Result & magnitude | Source |
|---|---|---|---|---|---|---|---|---|
Background | Meta-analysis Statistically combines results from multiple eligible studies; confidence still depends on the quality, consistency, and directness of those studies. | — | — | — | — | — | A 2021 meta-analysis of six randomized placebo-controlled trials involving 1,068 patients found that about one month of zolpidem treatment increased total sleep time, reduced sleep latency, and improved sleep quality versus placebo; wake after sleep onset did not significantly improve. | PubMed → |
Background | Observational research Observes real-world associations without assigning treatment, so confounding can limit causal conclusions. | — | — | — | — | — | A 2021 systematic review summarized zolpidem-associated complex sleep behaviors including sleepwalking and sleep-related eating; the evidence base was dominated by case reports, case series, and observational studies rather than randomized trials. | PubMed → |
Background | Other / unclear The study design is not yet classified clearly enough to infer its place in the evidence hierarchy. | — | — | — | — | — | Current U.S. labeling identifies zolpidem tartrate as a Schedule IV sedative-hypnotic indicated for short-term treatment of insomnia characterized by difficulty with sleep initiation and carries a boxed warning for complex sleep behaviors that can cause serious injury or death. | Source → |
Dosing
- No standardized dose
- No standardized dose is established for this ingredient in our source data. Preparations differ widely, so follow the standardization on the product you actually have and speak to a clinician before starting.
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Free safety checklist
Get the Zolpidem evidence notes
Occasional research updates, safety context, and product-quality checks for supplement decisions.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
Sourcing options disabled for safety
Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.
Evaluate the safety checks, contraindications, and potential medication interactions above under clinician supervision before use.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Help improve this profile
Was this useful for your research?
These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.
Was this evidence summary clear?
Did you find what you were researching?